dstock - From the data readout: "Four of the 8 patients (50.0%) stopped receiving DCVax-L while using the TTF device post-recurrence, and survived from 8.9 to 29.2 months from randomization."
This specific revelation is yet another ah ha moment, and self explanatory. While I disagree that it proves the ineffectiveness of the helmet, what it does show, in order to achieve optimal survival, DCVax is indispensable for achieving that end.
It would be interesting to learn why the DCVAX was stopped? Nonetheless, the data is quite illuminating to say the least.
ILT
Market Data 
Markets 
AI
